DT07 Rec'd PCT/PTO 0 2 FEB 2005

			
Form PT (REV 5-9		IMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER B45314
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED / ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) Unkno 10/523114	
	NATIONAL APPLICATION NO. EP2003/008567	INTERNATIONAL FILING DATE 31 July 2003	PRIORITY DATE CLAIMED 2 August 2002 (earliest date)
TITLE	OF INVENTION		
Vacc	ine Composition Compri	sing Transferrin Binding Prot	ein and HSF From Gram Negative
Bacte	eria		
APPLIC	CANT(S) FOR DO/EO/US		
Franc	ois-Xavier BERTHET, I	Ralph BIEMANS, Philippe D	ENOEL, Christiane FERON, Karine
GOR	AJ, Jan POOLMAN, Vir	ncent WEYNANTS	
Applic	ant herewith submits to the Ur	nited States Designated/Elected Offi	ice (DO/EO/US) the following items and
other in	nformation:	3.	
_	_		
- I	-	of items concerning a filing under	
2. []			ncerning a filing under 35 U.S.C. 371.
3. [x			(35 U.S.C. 371(f)) at any time rather than nit set in 35 U.S.C. 371(b) and PCT
4. [x		national Preliminary Examination wa	as made by the 19th month from the earliest
5. [x	- · ·	Application as filed (35 U.S.C. 371)	
		ith (required only if not transmitted	by the International Bureau).
		by the International Bureau.	
	c. [] is not required, as the	e application was filed in the United	d States Receiving Office (RO/US).
6. []	A translation of the Internat	ional Application into English (35 U	J.S.C. 371(c)(2)).
7. []	Amendments to the claims of	of the International Application unde	er PCT Article 19 (35 U.S.C. 371(c)(3))
		with (required only if not transmitte	
	b. [] have been transmitted	ed by the International Bureau.	
		•	such amendments has NOT expired.
		and will not be made.	ı
8. []		nents to the claims under PCT Articl	e 19 (35 U.S. C. 371(c)(3)).
9. []	An oath or declaration of the	e inventor(s) (35 U.S.C. 371(c)(4)).	
то. []	U.S.C. $371(c)(5)$).	to the International Preliminary Ex	amination Report under PCT Article 36 (35
Items 1	1. to 16. below concern other	er document(s) or information inc	
		Statement under 37 C.F.R. 1.97 and	
		r recording. A separate cover sheet	
[]	and 3.31 is included.	recording. Trisoparate cover sneet	in compliance with 57 C.I. IX. 5.25
13. [x]	A FIRST preliminary amen	dment.	
	(Add claim to priority via	Preliminary Amendment for US	originating cases only)
14. []	A SECOND or SUBSEQUE	ENT preliminary amendment.	
15. []	A substitute specification.		
	Power of attorney.		
	An Abstract on a separate sh		
	Copy of Form PCT/ISA/210).	
19. []	Other items or information.		

US APPLICATION NO. (if known see 37 CFR 1.50) Unknown 10/523114 INTERNATIONAL APPLICATION NO. PCT/EP2003/008567				ATTORNEYS DOCKE B45314	ET NO.
20. [X] The following fees are submitted:				CALCULATION	PTO USE ONLY
Basic	National Fee (37 C.I	F.R. 1.492(a)(1)-(5)):			
🗷 a) Bas	ic Filing Fee		\$300.00		
🗷 b) Exa	mination Fee		\$200.00		
		TOTAL OF ABOV	E CALCULATIONS =	\$1,000.00	
		oath or declaration la		\$0.00	
months from the	earliest claimed priori	ty date (37 CFR 1.492	(e)).		
Claims	Number Filed	Number Extra	Rate		
Total claims	71 - 20 =	51	51 x \$50.00	\$2550.00	
Independent	4 - 3 =	1	1 x \$200.00	\$200.00	
claims			+ \$360.00		
Multiple depende	nt claims (if applicable	\$0.00			
		TOTAL OF ABOV	VE CALCULATIONS =	\$2,750.00	
National Stage Ap	pplication size fee - fo	or each additional 50 s	heets that exceed 100	\$0.00	
sheets. No. of 50 addt'l sheets $\underline{0}$ x \$250.00 =					
SUBTOTAL =				\$3,750.00	
	Processing fee of \$130.00 for furnishing the English translation later than				
□ 20 □ 30 months from the earliest claimed priority date (37 CFR 1.492(f)) +					
TOTAL NATIONAL FEE =				\$3,750.00	
				Amount to be	\$
	<u></u>				
				charged	\$

9	A check in the amount of \$	to cover the above fees is enclosed

- b. Please charge my Deposit Account No. 19-2570 in the amount of \$3,750.00 to cover the above fees.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

GLAXOSMITHKLINE

Corporate Intellectual Property - UW2220

P.O. Box 1539

King of Prussia, PA 19406-0939

Phone (610) 270-6150

Facsimile (610) 270-5090

SIGNATURE

Sason C. Fedon

NAME

48,138

REGISTRATION NO.

n:\jcf\apps\b-cases\b45315\nat'l transmittal.doc

10/523114 DT05 Rec'd PCT/PTO 0.2 FEB 2005

"EXPRESS MAIL CERTIFICATE"

"EXPRESS MAIL" MAILING LABEL NUMBER EV608166135US DATE OF DEPOSIT <u>2 February 2005</u>

I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE "EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE UNDER 37 CFR 1.10 ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

NAME OF PERSON MAILING PAPER OR FEE

(TYPE OR PRINT) Longe Myers
SIGNATURE Sonaie Mys

Attorney Docket No.: B45314

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Berthet et al. 2 February 2005

Int'l Serial No.: PCT/EP2003/008567 Group Art Unit No.: unknown

Int'l Filing Date: 31 July 2003 Examiner: unknown

For: Vaccine Composition Comprising Transferrin Binding Protein and HSF

From Gram Negative Bacteria

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 CFR §§ 1.821 THROUGH 1.825

Commissioner for Patents Mail Stop: Sequence P.O. Box 1450 Alexandria, Va 22313-1450

(X)	I hereby state that the contents of the paper and computer readable copies of
	the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e),
	respectively, are the same.

)	I hereby state that the submission filed in accordance with 37 CFR §1.821 (g
	does not include new matter.

()	I hereby state that the submission filed in accordance with 37 CFR §1.821 (h)
		does not include new matter or go beyond the disclosure in the international
		application as filed.

)	I hereby state that the amendments, made in accordance with 37 CFR §1.825
	(a), included in the substitute sheet(s) of the Sequence Listing are supported in
	the application, as filed, at pages I hereby state that the substitute
	sheet(s) of the Sequence Listing does (do) not include new matter.

() I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(b), is the same as the amended Sequence Listing.

International Serial No.: PCT/EP2003/008567
International Filing Date: 31 July 2003

() I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(d), is identical to that originally filed.

Respectfully submitted,

Jason C. Fedon
Agent for Applicants
Registration No. 48,138

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-6150
Facsimile (610) 270-5090
N:UCF\apps\B-Cases\B45314\Sequence Listing Transmittal.doc